Parkinson's Disease最新文献

{"title":"Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease.","authors":"Kristina Rosqvist,&nbsp;Per Odin","doi":"10.1155/2023/6667339","DOIUrl":"https://doi.org/10.1155/2023/6667339","url":null,"abstract":"<p><strong>Background: </strong>National as well as international Parkinson's disease (PD) treatment guidelines are available to guide clinicians. Previous research has shown that nonmotor symptoms (NMS) are pronounced in late-stage PD and has suggested that current treatment is insufficient and could be improved.</p><p><strong>Objectives: </strong>The aim of this study was to investigate to which degree the national and international treatment guidelines are followed in the treatment of NMS in late-stage PD.</p><p><strong>Methods: </strong>This Swedish cohort was part of the Care of Late-Stage Parkinsonism (CLaSP) study. Late-stage PD was defined as Hoehn and Yahr stages IV-V in \"on\" and/or ≤50% on the Schwab and England Activities of Daily Living (ADL) scale. NMS were assessed with the NMS scale (NMSS), cognition with the Mini-Mental State Examination (MMSE), and depressive symptoms with the Geriatric Depression Scale (GDS-30). Symptomatic individuals were defined as ≥ 6 on an item of the NMSS; for dementia, a cutoff of ≤18 on the MMSE; for depression, a cutoff of ≥10 on the GDS.</p><p><strong>Results: </strong>All 107 participants exhibited NMS to various degrees and severities; the median NMSS score was 91. Among symptomatic individuals, for depressive symptoms, 37/63 (59%) were treated with antidepressants; for hallucinations and delusions, 9/18 (50%) and 5/13 (38%) were treated with antipsychotics; and for dementia, 9/27 (33%) were treated with rivastigmine and 1 (4%) was treated with donepezil. For orthostatic hypotension, 11/19 (58%) with lightheadedness and 7/8 (88%) with fainting were treated with antihypotensives; for sialorrhea, 2/42 (5%) were treated with botulinum toxin; and for constipation, 19/35 (54%) were treated with laxatives. For insomnia, 4/16 (25%) were treated with hypnotics, and for daytime sleepiness, 1/29 (3%) was treated with psychostimulants.</p><p><strong>Conclusions: </strong>The present analyses suggest a need for clinicians to further screen for and treat NMS. Optimizing treatment of NMS according to the national and international treatment guidelines may improve symptomatology and enhance quality of life in late-stage PD.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"6667339"},"PeriodicalIF":3.2,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49680900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levodopa Prescription Patterns in Patients with Advanced Parkinson's Disease: A Japanese Database Analysis.","authors":"Atsushi Takeda,&nbsp;Toru Baba,&nbsp;Jun Watanabe,&nbsp;Masahiko Nakayama,&nbsp;Hiroyuki Hozawa,&nbsp;Miwako Ishido","doi":"10.1155/2023/9404207","DOIUrl":"10.1155/2023/9404207","url":null,"abstract":"<p><p>Prescription doses of levodopa in patients with advanced Parkinson's disease (PD) are generally lower in Japan than in the United States or Europe, although Japanese guidelines for the management of PD recommend increasing the dosage as the disease progresses. However, data regarding levodopa prescription practices in patients with advanced PD in the clinical setting are limited. This retrospective observational study analyzed patterns of drug use for patients with advanced PD in Japan using claims data from hospitalized patients in the Medical Data Vision Co. database. Eligible patients had at least two PD-associated claims in two different quarters between April 1, 2008, and November 30, 2018, and a 10-item activities of daily living score <60 upon hospital discharge (as a proxy for advanced PD). The primary endpoint was the prescribed dosage of levodopa at the index hospitalization. Dosages of other PD drugs (medications with an on-label indication for PD) and non-PD drugs were also assessed. Overall, 4029 patients met the inclusion criteria (mean age, 76.9 years; 83.3% aged ≥70 years). At the index date, 74.0% were receiving levodopa. Patients received a median of one PD drug in addition to levodopa, and 27.4% and 20.2% received one or two concomitant PD drugs, respectively. Patients received a median of two non-PD drugs. The median levodopa dosage and total levodopa equivalent dosage (LED) at the index hospitalization were 418.2 and 634.8 mg/day (adjusted for body weight, 9.0 and 13.7 mg/kg/day), respectively. The median levodopa and total LED dosage in each 6-month increment during the 5 years before and after the index date ranged between 263.9 and 330.2 mg/day (5.0 and 6.5 mg/kg/day) and 402.0 and 504.9 mg/day (8.3 and 10.1 mg/kg/day), respectively. This study suggests that many Japanese patients with advanced PD could receive more intensive treatment with higher doses of levodopa.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"9404207"},"PeriodicalIF":3.2,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41179685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.","authors":"Zijuan Zhang,&nbsp;Ming Shi,&nbsp;Zhengmin Li,&nbsp;Yuan Ling,&nbsp;Luke Zhai,&nbsp;Ye Yuan,&nbsp;He Ma,&nbsp;Li Hao,&nbsp;Zhonghua Li,&nbsp;Zhenqiang Zhang,&nbsp;Christian Hölscher","doi":"10.1155/2023/7427136","DOIUrl":"https://doi.org/10.1155/2023/7427136","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a complex syndrome with many elements, such as chronic inflammation, oxidative stress, mitochondrial dysfunction, loss of dopaminergic neurons, build-up of alpha-synuclein (<i>α</i>-syn) in cells, and energy depletion in neurons, that drive the disease. We and others have shown that treatment with mimetics of the growth factor glucagon-like peptide 1 (GLP-1) can normalize energy utilization, neuronal survival, and dopamine levels and reduce inflammation. Liraglutide is a GLP-1 analogue that recently showed protective effects in phase 2 clinical trials in PD patients and in Alzheimer disease patients. We have developed a novel dual GLP-1/GIP receptor agonist that can cross the blood-brain barrier and showed good protective effects in animal models of PD. Here, we test liraglutide against the dual GLP-1/GIP agonist DA5-CH (KP405) in the A53T tg mouse model of PD which expresses a human-mutated gene of <i>α</i>-synuclein. Drug treatment reduced impairments in three different motor tests, reduced levels of <i>α</i>-syn in the substantia nigra, reduced the inflammation response and proinflammatory cytokine levels in the substantia nigra and striatum, and normalized biomarker levels of autophagy and mitochondrial activities in A53T mice. DA5-CH was superior in almost all parameters measured and therefore may be a better drug treatment for PD than liraglutide.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"7427136"},"PeriodicalIF":3.2,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41129491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mercury and Parkinson's Disease: Promising Leads, but Research Is Needed.","authors":"E Fuller Torrey,&nbsp;Wendy Simmons","doi":"10.1155/2023/4709322","DOIUrl":"https://doi.org/10.1155/2023/4709322","url":null,"abstract":"<p><p>Environmental toxicants are thought to play a major role in the pathogenesis of Parkinson's disease. In reviewing the literature on heavy metals known to be toxicants, we noted several recent studies on mercury suggesting a possible role in the etiology of some cases of this disease. We therefore undertook a review of this association, focusing especially on peer-reviewed articles to avoid the bias inherent in much of the literature regarding mercury. For most people, our contemporary exposure to mercury comes from dental amalgam tooth restorations and from eating fish contaminated with mercury. In both cases, mercury is known to get into the brain in utero and at all ages. It remains in the brain for many years and is known to produce permanent neuropsychological deficits. Mercury toxicity can produce tremors and other Parkinsonian clinical symptoms. It can also produce neurochemical and neuropathological changes similar to those found in Parkinson's disease, including the loss of dopamine neurons, degeneration of tubulin and axons, dysfunction of mitochondria, and the aggregation of alpha-synuclein. Relatively few studies have assessed mercury in parkinsonian patients, but almost all reported a statistically significant association. Published studies suggest some promising leads in the relationship between mercury exposure and Parkinson's disease. However, studies of patients are relatively few, and the need for research is clear. A search of Parkinsonian research studies currently funded by the US National Institutes of Health, Parkinson's Foundation, and the Michael J Fox Foundation yielded no studies on mercury. We believe such studies should be supported.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"4709322"},"PeriodicalIF":3.2,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41146771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative Analysis of Attitudes, Knowledge, and Interest in Research of People with Parkinson's Disease and Their Care Partners Receiving Accessible Research Education.","authors":"Maria E Ramos, Suraj Pothineni, Liang Ni, Allison A Bay, Todd Prusin, Madeleine E Hackney","doi":"10.1155/2023/5519646","DOIUrl":"10.1155/2023/5519646","url":null,"abstract":"<p><strong>Background: </strong>People with Parkinson's disease (PWP) and their care partners (CP) are underrepresented in research.</p><p><strong>Methods: </strong>As an eight-week research advocacy training program, TeleDREAMS was designed to increase understanding of, and participation in, clinical research by older adults through topics on the research process. Qualitative analysis was conducted to explore themes from 365 thirty-minute semistructured phone interviews with 32 PWP and 17 CP TeleDREAMS participants. Interviews gauged progress, motivation, and information retention after each weekly module.</p><p><strong>Results: </strong>Eight salient themes were identified from the interviews, including Understanding the Importance of Advocacy and Becoming Cognizant of Past Advocacy Experiences.</p><p><strong>Conclusions: </strong>While some findings aligned with weekly module topics, others, such as stated learning preferences and knowledge acquisition of older adults in an educational program, were unexpected. TeleDREAMS may increase interest in community engagement, research participation, and advocacy roles in marginalized and underrepresented participants.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"5519646"},"PeriodicalIF":2.1,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41147538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rehabilitative Effect of Archery Exercise Intervention in Patients with Parkinson's Disease.","authors":"Chiu-Ying Chen,&nbsp;Wei-Ning Wang,&nbsp;Ming-Kuei Lu,&nbsp;Yu-Wan Yang,&nbsp;Tsung Yu,&nbsp;Trong-Neng Wu,&nbsp;Chon-Haw Tsai","doi":"10.1155/2023/9175129","DOIUrl":"10.1155/2023/9175129","url":null,"abstract":"<p><strong>Background: </strong>Archery exercise exerts a rehabilitative effect on patients with paraplegia and might potentially serve as complementary physiotherapy for patients with Parkinson's disease.</p><p><strong>Objective: </strong>This study aimed to examine the rehabilitative effects of an archery intervention.</p><p><strong>Methods: </strong>A randomized controlled trial of a 12-week intervention was performed in patients with idiopathic Parkinson's disease. Thirty-one of the 39 eligible patients recruited from a medical center in Taiwan participated in the trial, of whom 16 were in the experimental group practicing archery exercises and 15 were in the control group at the beginning; twenty-nine completed the whole process. The Purdue pegboard test (PPT), the Unified Parkinson's Disease Rating Scale I to III (UPDRS I to III), physical fitness test, and timed up and go test (TUG) were used to assess the intervention effects of archery exercise.</p><p><strong>Results: </strong>Compared to the control group, the outcome differences between the posthoc and baseline tests in PPT, UPDRS I to III, lower extremity muscular strength, and TUG in the experimental group (between-group difference in difference's mean: 2.07, 1.59, 1.36, -2.25, -3.81, -9.10, 3.57, and -1.51, respectively) did show positive changes and their effect sizes examined from Mann-Whitney <i>U</i> tests (<i>η</i>: 0.631, 0.544, 0.555, 0.372, 0.411, 0.470, 0.601, and 0.381, respectively; Ps < 0.05) were medium to large, indicating that the archery intervention exerted promising effects on improving hand flexibility and finger dexterity, activity functions in motor movement, lower extremity muscular strength, and gait and balance ability.</p><p><strong>Conclusions: </strong>Traditional archery exercise was suggested to have a rehabilitative effect for mild to moderate Parkinson's disease and could be a form of physiotherapy. Nevertheless, studies with larger sample sizes and extended intervention periods are needed to ascertain the long-term effects of archery exercise.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"9175129"},"PeriodicalIF":3.2,"publicationDate":"2023-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dyrk1a Phosphorylation of <i>α</i>-Synuclein Mediating Apoptosis of Dopaminergic Neurons in Parkinson's Disease.","authors":"Yuxuan Yong,&nbsp;Qinfen Wu,&nbsp;Xinling Meng,&nbsp;Ranran Lu,&nbsp;Huan Xia,&nbsp;Feifei Pei,&nbsp;Xinling Yang","doi":"10.1155/2023/8848642","DOIUrl":"https://doi.org/10.1155/2023/8848642","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role of aberrant Dyrk1a expression in phosphorylation modification at the <i>α</i>-synuclein serine 129 (Ser129) site to analyze its molecular mechanism in mediating apoptosis of PD.</p><p><strong>Methods: </strong>The protein level of P-<i>α</i>-synuclein (Ser129), <i>α</i>-synuclein, Bcl-2, Bax, active caspase 3, GSK3<i>β</i>, PI3K, AKT, and cyclinD1 were detected. The mRNA transcript levels of Dyrk1a and DAT and protein levels of IL-1<i>β</i>, IL-6, COX-2, and TNF-<i>α</i> were detected.</p><p><strong>Results: </strong>P-<i>α</i>-synuclein (Ser129), <i>α</i>-synuclein, Bax, active caspase 3, GSK3<i>β</i>, and cyclinD1 expressions were decreased in Dyrk1a-AAV-ShRNA (<i>P</i> < 0.05), and Bcl-2, AKT, and PI3K expressions were increased (<i>P</i> < 0.05). Increased TH protein expression was shown in Dyrk1a-AAV-ShRNA (<i>P</i> < 0.05). Dyrk1a mRNA was decreased in the Dyrk1a-AAV-ShRNA group (<i>P</i> < 0.05), and DAT mRNA was increased (<i>P</i> < 0.05). IL-1<i>β</i>, IL-6, COX-2, and TNF-<i>α</i> protein levels were decreased in Dyrk1al-AAV-Sh-RNA (<i>P</i> < 0.05). Transcriptome sequencing showed that Fam220a, which was expected to activate STAT family protein binding activity and participate in the negative regulation of transcription through RNA polymerase II and protein dephosphorylation showed differentially upregulated expression. The untargeted metabolome showed that the major compounds in the Dyrk1a-AAV-ShRNA group were hormones and transmission mediators and the most metabolism-related pathways. Fam220a showed differentially upregulated expression, and differentially expressed genes were enriched for the neuroactive ligand-receptor interaction, vascular smooth muscle contraction, and melanogenesis-related pathways.</p><p><strong>Conclusion: </strong>Abnormal Dyrk1a expression can affect <i>α</i>-synuclein phosphorylation modifications, and dyrk1a knockdown activates the PI3K/AKT pathway and reduces dopaminergic neuron apoptosis. It provides a theoretical basis for the group to further investigate the molecular mechanism.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"8848642"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9898905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementary Motor Area Activity Differs in Parkinson's Disease with and without Freezing of Gait.","authors":"J Sebastian Marquez,&nbsp;Ronny P Bartsch,&nbsp;Moritz Günther,&nbsp;S M Shafiul Hasan,&nbsp;Or Koren,&nbsp;Meir Plotnik,&nbsp;Ou Bai","doi":"10.1155/2023/5033835","DOIUrl":"https://doi.org/10.1155/2023/5033835","url":null,"abstract":"<p><p>The study aimed to investigate the neural changes that differentiate Parkinson's disease patients with freezing of gait and age-matched controls, using ambulatory electroencephalography event-related features. Compared to controls, definite freezers exhibited significantly less alpha desynchronization at the motor cortex about 300 ms before and after the start of overground walking and decreased low-beta desynchronization about 300 ms before and about 300 and 700 ms after walking onset. The late slope of motor potentials also differed in the sensory and motor areas between groups of controls, definite, and probable freezers. This difference was found both in preparation and during the execution of normal walking. The average frontal peak of motor potential was also found to be largely reduced in the definite freezers compared with the probable freezers and controls. These findings provide valuable insights into the underlying structures that are affected in patients with freezing of gait, which could be used to tailor drug development and personalize drug care for disease subtypes. In addition, the study's findings can help in the evaluation and validation of nonpharmacological therapies for patients with Parkinson's disease.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"5033835"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Non-Motor Symptoms Scale for Parkinson's Disease of Persian Version.","authors":"Zahra Eghlidos,&nbsp;Aida Abolhassanbeigi,&nbsp;Zahra Rahimian,&nbsp;Samaneh Khazraei,&nbsp;Vahid Reza Ostovan","doi":"10.1155/2023/1972034","DOIUrl":"https://doi.org/10.1155/2023/1972034","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess the validity and reliability of the Persian version of the NonMotor Symptoms Scale (NMSS) in Iranian patients with PD.</p><p><strong>Methods: </strong>This cross-sectional study was conducted in patients with PD. After the cross-cultural adaptation of the NMSS, the acceptability, reliability, precision, and validity of the Persian NMSS were evaluated. For this purpose, in addition to NMSS, we used the following measures: Scales for Outcomes in Parkinson's Disease (SCOPA)-Autonomic (SCOPA-AUT), SCOPA-Sleep, Beck's Depression Inventory (BDI) questionnaire, Parkinson's Disease Questionnaire-8 questions (PDQ-8), SCOPA-Motor, SCOPA-Psychiatric Complications (SCOPA-PC), SCOPA-Cognition (SCOPA-COG), Mini-Mental State Examination (MMSE), Hoehn and Yahr Staging (H and Y), and Unified Parkinson Disease Rating Scale (UPDRS).</p><p><strong>Results: </strong>186 patients were enrolled <b>(</b>mean age 64.46 ± 9.9 years; disease duration 5.59 ± 3.99 years; 118 (63.4%) male; mean NMSS score 52.01 ± 38.54). Neither the floor effect (2.7%) nor the ceiling effect (0.5%) was seen in NMSS total score. Cronbach's alpha of total NMSS was 0.84. The test-retest reliability was 0.93 for the NMSS total and 0.81-0.96 for domains. The standard error of measurement (SEM) was lower than half of the standard deviation for NMSS total and all domains. NMSS total showed a high correlation with UPDRS I (<i>r</i>_<i>s</i> = 0.84), UPDRS II (<i>r</i>_<i>s</i> = 0.58), PDQ-8 (<i>r</i>_<i>s</i> = 0.61), BDI (<i>r</i>_<i>s</i> = 0.71), SCOPA-sleep (<i>r</i>_<i>s</i> = 0.60), and SCOPA AUT (<i>r</i>_<i>s</i> = 0.66). NMSS has an acceptable discriminative validity based on disease duration and severity of disease according to H and Y staging.</p><p><strong>Conclusion: </strong>The Persian NMSS is a valid and reliable measure for evaluating the burden of nonmotor symptoms in Iranian patients with PD.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"1972034"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Analysis of Postural Balance in Faller and Nonfaller Patients with Parkinson's Disease.","authors":"Do Young Kwon,&nbsp;Yuri Kwon,&nbsp;Ji-An Choi,&nbsp;Junghyuk Ko,&nbsp;Ji-Won Kim","doi":"10.1155/2023/9688025","DOIUrl":"https://doi.org/10.1155/2023/9688025","url":null,"abstract":"<p><strong>Background: </strong>Postural instability has been identified as a fall risk factor with a significant impact on the quality of life of patients with Parkinson's disease (PD). The aim of this study was to compare the center of pressure (COP) between faller and nonfaller patients with PD during static standing.</p><p><strong>Methods: </strong>Thirty-two faller patients and 32 nonfaller patients with PD participated in this study. All patients performed the static balance test on a force plate. COP data were recorded during quiet standing. Mean distance, sway area, mean velocity, mean frequency, and peak power were derived from the COP data. Statistical analysis was performed using independent <i>t</i>-tests to compare faller and nonfaller patients.</p><p><strong>Results: </strong>Fallers presented a greater average distance, wider sway area, faster average speed, and greater peak power than nonfallers (<i>p</i> < 0.05). In contrast, no significant group differences were observed in peak frequency and mean frequency (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>Although falls occur during dynamic activities, our study demonstrated that even a safe and simple static postural balance test could significantly differentiate between faller and nonfaller patients. Thus, these results suggest that quantitatively assessed static postural sway variables would be useful for distinguishing prospective fallers among PD patients.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"9688025"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}